In the MR CLEAN randomized clinical trial, modern endovascular stroke therapies doubled the odds of a good neurological outcome in patients with severe ischemic stroke and documented intracranial large-artery occlusion.
The failure of endovascular stroke therapy to improve outcomes in several recent randomized trials may have been related to the use of first-generation thrombectomy devices and the potential inclusion of patients without proximal arterial occlusion (NEJM JW Neurol Mar 5 2013). To address these limitations, the MR CLEAN randomized, multicenter, partially industry-supported trial evaluated predominantly new-generation, retrievable stents in patients with documented proximal vessel occlusion. Researchers enrolled 500 patients (mean age, 65; range, 23–96; median National Institutes of Health Stroke Scale score, approximately 18), of whom 89% received intravenous alteplase before randomization. Fewer than 25% of patients had significant ischemia…
Reviewing Author
DisclosuresSpeaker’s bureauGenentech
Grant / Research supportNational Institutes of Health/National Institute of Neurological Disorders and Stroke; Michael Goldberg Stroke Research Fund
Editorial boardsPLOS One; Scientific Reports
Leadership positions in professional societiesNeurocritical Care Society (Research Committee Member)
DisclosuresSpeaker’s bureauGenentech
Grant / Research supportNational Institutes of Health/National Institute of Neurological Disorders and Stroke; Michael Goldberg Stroke Research Fund
Editorial boardsPLOS One; Scientific Reports
Leadership positions in professional societiesNeurocritical Care Society (Research Committee Member)